Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome

This study has been completed.

First Received on September 19, 2005. Last Updated on October 18, 2007 History of Changes

Sponsor:	Astellas Pharma Inc
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00239317

Purpose

The purpose of this study is to determine whether Tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.

Condition	Intervention	Phase
Urinary Tract Diseases	Drug: Tamusulosin	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Tamsulosin Tamsulosin hydrochloride

U.S. FDA Resources

Further study details as provided by Astellas Pharma Inc:

Eligibility

Criteria

Inclusion Criteria:

Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs).

Exclusion Criteria:

Patients with urination disorder accompanied by apparent organic(benign prostatic hyperplasia: BPH) or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00239317

Locations

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

Study Director:

Study Director

Clinical Development, Astellas Pharma Inc.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00239317 History of Changes
Other Study ID Numbers:	B617/LCT3
Study First Received:	September 19, 2005
Last Updated:	October 18, 2007
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Astellas Pharma Inc:

tamsulosin
urinary tract diseases
male

Additional relevant MeSH terms:

Urologic Diseases
Tamsulosin
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists

Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 09, 2012